KLK3 and cancer: In conclusion, we propose an improved volatile urinary biomarker panel to simultaneously discriminate PCa from cancer-free subjects and carriers of other common urological cancers, holding the potential for the development of a non-invasive early detection tool for PCa that outperforms serum PSA sensitivity and accuracy.